Patritumab - Amgen/Daiichi Sankyo
Alternative Names: AMG-888; U3-1287Latest Information Update: 30 Jul 2024
At a glance
- Originator Amgen; U3 Pharma
- Developer Daiichi Sankyo Company; U3 Pharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 30 Jul 2024 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan (IV)
- 30 Jul 2024 Discontinued - Phase-I for Solid tumours in USA (IV)
- 30 Jul 2024 Discontinued - Phase-II for Head and neck cancer (Combination therapy, First-line therapy, Metastatic disease) in Belgium (IV)